122 related articles for article (PubMed ID: 6403561)
21. Urinary excretion of 5-S-cysteinyldopa in healthy Japanese.
Morishima T; Hanawa S
Acta Derm Venereol; 1981; 61(2):149-50. PubMed ID: 6165192
[TBL] [Abstract][Full Text] [Related]
22. Quantitative determination of 5-S-cysteinyldopa, dopa and dopamine in the urine by means of high-performance liquid chromatography. A comparison with data obtained by means of fluorometry.
Morishima T; Saito M; Hanawa S
J Dermatol; 1981 Aug; 8(4):301-4. PubMed ID: 6795251
[No Abstract] [Full Text] [Related]
23. Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
Jönsson PE; Agrup G; Arnbjörnsson E; Hafström L; Rorsman H
Cancer; 1980 Jan; 45(2):245-8. PubMed ID: 6153150
[TBL] [Abstract][Full Text] [Related]
24. [Comparative studies between excretion of 5-S-cysteinyldopa and indole melanogens in urine].
Beyer C; Fiedler H; Wohlrab W; Wozniak KD
Dermatol Monatsschr; 1986; 172(9):541-4. PubMed ID: 3098590
[No Abstract] [Full Text] [Related]
25. Urinary excretion of melanocytic metabolites in fertile women.
Carstam R; Hansson C; Rorsman H; Rosengren E; Sjöberg NO; Wirestrand LE
Acta Derm Venereol; 1985; 65(6):543-5. PubMed ID: 2420122
[TBL] [Abstract][Full Text] [Related]
26. Synthesis of 5-S-L-cysteinyl-glycine-L-dopa, a natural substrate for serum and melanocyte dipeptidase.
Kågedal B; Gawelin AL; Pettersson A
Anal Biochem; 1987 Aug; 165(1):167-74. PubMed ID: 3120620
[TBL] [Abstract][Full Text] [Related]
27. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
28. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
Inoi T; Mojamdar M; Ichihashi M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
[No Abstract] [Full Text] [Related]
29. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
Inoi T; Mojamdar M; Ichihashi M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1984 Jan; 94(1):39-43. PubMed ID: 6433083
[No Abstract] [Full Text] [Related]
30. Diastereomers of 5-S-cysteinyldopa.
Agrup G; Edholm LE; Rorsman H; Rosengren E
Acta Derm Venereol; 1983; 63(1):59-61. PubMed ID: 6191491
[TBL] [Abstract][Full Text] [Related]
31. Plasma 5-S-cysteinyldopa concentrations in oculocutaneous albinism.
Nimmo JE; Hunter JA; Percy-Robb IW; Jay B; Phillips CI; Taylor WO
Acta Derm Venereol; 1985; 65(2):169-71. PubMed ID: 2408424
[TBL] [Abstract][Full Text] [Related]
32. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
[TBL] [Abstract][Full Text] [Related]
33. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
34. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease].
Hanawa S
Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952
[No Abstract] [Full Text] [Related]
35. Seasonal variation in urinary excretion of 5-S-cysteinyldopa in healthy Japanese.
Ito S; Kato T; Fujita K
Acta Derm Venereol; 1987; 67(2):163-5. PubMed ID: 2438883
[TBL] [Abstract][Full Text] [Related]
36. Identification of 5-S-cysteinyldopa by high performance liquid chromatography in biopsies from patients with dysplastic melanocytic nevi.
Halldin MM; Cook WS; Kawashima T; Crutcher WA; Fukuyama K
Cancer Res; 1987 Jan; 47(2):636-8. PubMed ID: 3098416
[TBL] [Abstract][Full Text] [Related]
37. UVB-induced melanocyte proliferation and 5-S-cysteinyldopa excretion in dysplastic nevus syndrome.
Stierner U; Augustsson A; Rosdahl I; Kågedal B; Suurküla M
Photodermatol; 1988 Oct; 5(5):218-23. PubMed ID: 3146749
[TBL] [Abstract][Full Text] [Related]
38. Excretion of 5-s-cysteinyldopa in humans with genetically dark skin.
Agrup G; Hansson C; Juldorf F; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(1):69-70. PubMed ID: 84471
[TBL] [Abstract][Full Text] [Related]
39. Sensitive high-performance liquid chromatographic method for the determination of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid and 5-S-cysteinyl-3,4-dihydroxyphenylalanine.
Fornstedt-Wallin B; Bergh I
J Chromatogr B Biomed Appl; 1995 Jan; 663(1):9-14. PubMed ID: 7704217
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
Agrup G; Hafström L; Jönsson PE; Rorsman H
Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
